Abstract
Michael A. Campitelli, MPH; Susan E. Bronskill, PhD; Laura C. Maclagan, MSc; Daniel A. Harris, MPH; Cecilia A. Cotton, PhD; Mina Tadrous, PharmD, PhD; Andrea Gruneir, PhD; David B. Hogan, MD; Colleen J. Maxwell, PhD
Highlights
The pharmacoepidemiologic study by Campitelli et al[1] examined changes in medication prescribing in nursing homes in Ontario, Canada, during the first wave of the COVID-19 pandemic
More than 15 000 Ontario nursing home residents have been diagnosed with SARS-CoV-2, with nearly 4000 COVID-19 deaths.[2]
In Ontario, approximately 70% of residents live with dementia, and responsive behaviors that may have otherwise been addressed by nonpharmacologic interventions, such as social engagement, may instead have been treated with psychotropic medications that have long been the target of deprescribing initiatives in nursing homes
Summary
The pharmacoepidemiologic study by Campitelli et al[1] examined changes in medication prescribing in nursing homes in Ontario, Canada, during the first wave of the COVID-19 pandemic. Ontario has 626 nursing homes that house nearly 80 000 residents under a publicly funded long-term care program.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
